# Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

> **NCT03728972** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 19 (actual)

## Conditions studied

- NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis)
- NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03728972
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-09
- **Primary completion:** 2025-06-15
- **Final completion:** 2026-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728972, "Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03728972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*